Regeneron Reports Second Quarter 2019 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Regeneron (REGN) Tops Q2 EPS by 61c, Revenues Beat
August 6, 2019 6:43 AM EDTRegeneron (NASDAQ: REGN) reported Q2 EPS of $6.02, $0.61 better than the analyst estimate of $5.41. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.8 billion.
Second quarter 2019 revenues increased 20% to $1.93 billion versus second quarter 2018EYLEA® U.S. net sales increased 17% to $1.16 billion versus second quarter 2018Dupixent® global net sales, which are recorded by the Company's collaborator Sanofi, increased 166% to $557... More